For patients who have just been diagnosed with stage 3A lung cancer, many are advised to undergo neoadjuvant therapy before surgery. However, numerous questions arise, such as whether neoadjuvant therapy is necessary and what the procedure is, leaving patients and their families feeling confused.
We have specially invited Professor Yang Nong, a distinguished expert from Hainan Cancer Hospital/Affiliated Cancer Hospital of Hainan Medical University, to provide a detailed explanation of the neoadjuvant standard treatment for stage 3A lung cancer, based on authoritative guidelines for lung cancer diagnosis and treatment. This will help patients clarify their treatment approach and respond to the disease in a scientific manner.
Qustions & Answers
Q: What is preoperative neoadjuvant therapy?
Firstly, stage 3A lung cancer is classified as intermediate-stage lung cancer. Patients at this stage often exhibit mediastinal lymph node metastasis, but have not yet developed distant metastasis throughout the body, thus still presenting opportunities for curative surgery.
In simple terms, neoadjuvant therapy refers to systemic drug treatment administered before surgery. Its core function lies in shrinking the primary tumor lesion and reducing the extent of lymph node metastasis, thereby maximizing the probability of complete tumor resection during surgery. Additionally, it can eliminate microscopic latent cancer cells invisible to the naked eye, effectively reducing the risk of postoperative recurrence and improving the overall cure rate. It is a crucial component of standardized comprehensive treatment for stage 3A lung cancer.
Qustions & Answers
Q: Which patients are eligible for neoadjuvant therapy? What examinations should be completed before surgery?
To determine whether a patient with stage 3A lung cancer is suitable for neoadjuvant therapy, in addition to completing basic examinations such as routine imaging and physical examination, two core examinations are essential and serve as the basis for precision diagnosis and treatment.
The first is pathological biopsy, which is used to determine the specific pathological type of lung cancer and distinguish between different types such as non-small cell lung cancer and small cell lung cancer. This is the basic premise for treatment;
The second aspect involves gene testing and immune marker expression analysis. By analyzing the test results, we can determine the appropriate treatment approach for patients, precisely distinguishing between targeted neoadjuvant therapy, chemotherapy combined with immune neoadjuvant therapy, and other options. This provides a scientific basis for individualized diagnosis and treatment, avoiding blind treatment.
Qustions & Answers
Q: How to standardize the treatment of stage 3A lung cancer without driver gene mutations?
For stage 3A non-small cell lung cancer without driving gene mutations and unsuitable for targeted therapy, authoritative guidelines both domestically and internationally unanimously recommend immunotherapy combined with platinum-based doublet chemotherapy as the preferred neoadjuvant regimen.
The protocol consists of a treatment cycle every three weeks. After patients have completed four cycles of standardized treatment, a comprehensive review is needed to assess the treatment benefit. If the tumor shrinks significantly and metastatic lymph nodes are downgraded, meeting the surgical criteria, further evaluation can be conducted to consider performing radical surgery.
If there is no significant improvement in the condition after treatment and the lesion has not shrunk, and the difficulty of surgical resection remains high, the doctor will re-evaluate the condition and switch to other radical treatment options such as chemotherapy and radiotherapy.
The treatment of stage 3A lung cancer has moved away from a singular approach, with the core principle being multidisciplinary comprehensive diagnosis and treatment. It integrates various methods such as chemotherapy, immunotherapy, targeted therapy, and surgery to precisely combat tumors. For patients who are eligible for surgery, following the doctor's advice to complete neoadjuvant therapy before surgery is currently the most scientific and standardized approach to diagnosis and treatment.
Expert Introduction
Yang Nong, Chief Physician, Doctoral Supervisor
Long-term employed experts from Hainan Cancer Hospital/Affiliated Cancer Hospital of Hainan Medical University and Hainan Chengmei Hospital
He currently serves as Vice President of the Second People's Hospital of Hunan Province, head of the oncology department, and director of the "Yang Nong Famous Doctor Clinic" / "Yang Nong Famous Doctor Expert Team Clinic". He is also a chief expert of the National Major Scientific and Technological Special Project, a member of the Lung Cancer Special Committee of the National Tumor Quality Control Center, the director of the Hunan Provincial Key Laboratory of Precision Diagnosis and Treatment of Lung Cancer, and the director of the Hunan Provincial Respiratory Tumor Clinical Medicine Research Center. He has been dedicated to precision targeted therapy for lung cancer and gastrointestinal tumors, as well as to challenging, recurrent, and drug-resistant clinical cases, scientific research, and teaching for nearly 30 years.
He has been honored with the title of "National Famous Doctor - Excellent Style" in the 6th edition, and has been recommended as "Annual Good Doctor" by patients across the country for 8 consecutive years, as well as being awarded the title of "First Brain Doctor - Famous Doctor". He has authored national guidelines, boasts over 500,000 followers across the internet, and has achieved over 120 million views in cancer prevention and treatment science popularization.
Medical expertise
Specialties: Precision treatment of lung cancer, breakthrough in refractory, recurrent, and drug-resistant cases with brain metastasis; individualized and precise treatment of brain metastases from lung cancer; early diagnosis of pulmonary nodules and lung cancer; personalized and comprehensive diagnosis and treatment of solid tumors; clinical trials of the latest immunotherapy/targeted therapy drugs.
With nearly 30 years of experience in precision immunotherapy for lung cancer, he has led nearly 400 Phase I-III clinical trials of new anticancer drugs (including Class 1 national new drugs), and is particularly skilled in treating complex cases such as refractory, recurrent, and drug-resistant conditions, as well as brain metastases.
He is also proficient in the comprehensive diagnosis and treatment of multiple cancer types, individualized, and interdisciplinary, covering a wide range of solid tumors (such as stomach, intestine, brain, etc.).
[Visit Information]
1. Clinic Hours and Location
September 6, 14:00-17:00
Sixth Consultation Area of Hainan Cancer Hospital
2. [Appointment registration]
Follow the official account of Hainan Cancer Hospital for "appointment registration"
3. Health consultation
18976324546
[Friendly Reminder]
To help the expert understand your condition quickly, please bring the following:
1. ID card, medical insurance card, and mobile phone
2. Accompanying direct relatives (with decision-making authority)
3. Relevant previous examination results, organized chronologically
4. Paper medical records from previous consultations
5. Surgical case slides, wax blocks, or 20-30 glass slides
6. Pathological diagnosis report
7. Hospitalization medical records
8. Recent relevant examination results
9. The patients current treatment plan
10. The most urgent questions to consult